The invention relates to compounds of general formula (I), or a salt or solvate thereofin which:X and Y are each NA is an optionally substituted phenyl group or an optionally substituted sulphur containing heterocycleZ is a single bond or a linking group which is a carbon atom carrying substituents R4 and R5, wherein R4 and R5 are independently selected from hydrogen, optionally substituted C1-6 alkyl and another group A, provided that no more than one of R4 or R5 are hydrogenR1 is hydrogen, or a substituent group selected from C1-10 alkyl, C2-10 alkenyl, benzyl, piperidine-methyl, thienyl-methyl, furyl-methyl or C3-10 cycloalkyl, any of which is optionally substituted by hydroxy, halogen, carboxamide, halo C1-4 alkyl, C1-6 alkyl or C1-6 alkoxy or the Y nitrogen is unsubstitutedR2 is amino or a substituent group selected from optionally substituted alkyl or phenyl groups andN* is =NH when R1 is hydrogen or a substituent group orN* is a group NRaRb where Ra and Rb are independently H or an alkyl group orN* is an optionally substituted piperazinyl ring.The compounds can be used to treat disorders in mammals that are susceptible to sodium channel blockers and antifolates, particularly disorders such as epilepsy, multiple sclerosis, glaucoma and uveitis, cerebral traumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgical trauma, neurodegenerative disorders, motor neurone disease, Alzheimers disease, Parkinsons disease, chronic inflammatory pain, neuropathic pain, migraine, bipolar disorder, mood, anxiety and cognitive disorders, schizophrenia and trigeminal autonomic cephalalgias for treatment of mammalian cancers and for treatment of malaria.
